Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons

therapeutic implications for dystrophic epidermolysis bullosa

Jon Cogan, Jacqueline Weinstein, Xinyi Wang, Yingping Hou, Sabrina Martin, Andrew P. South, David T. Woodley, Mei Chen (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    31 Citations (Scopus)

    Abstract

    Patients with recessive dystrophic epidermolysis bullosa (RDEB) have severe, incurable skin fragility, blistering, and multiple skin wounds due to mutations in the gene encoding type VII collagen (C7), the major component of anchoring fibrils mediating epidermal-dermal adherence. Nearly 10-25% of RDEB patients carry nonsense mutations leading to premature stop codons (PTCs) that result in truncated C7. In this study, we evaluated the feasibility of using aminoglycosides to suppress PTCs and induce C7 expression in two RDEB keratinocyte cell lines (Q251X/Q251X and R578X/R906) and two primary RDEB fibroblasts (R578X/R578X and R163X/R1683X). Incubation of these cells with aminoglycosides (geneticin, gentamicin, and paromomycin) resulted in the synthesis and secretion of a full-length C7 in a dose-dependent and sustained manner. Importantly, aminoglycoside-induced C7 reversed the abnormal RDEB cell phenotype and incorporated into the dermal-epidermal junction of skin equivalents. We further demonstrated the general utility of aminoglycoside-mediated readthrough in 293 cells transiently transfected with expression vectors encoding 22 different RDEB nonsense mutations. This is the first study demonstrating that aminoglycosides can induce PTC readthrough and restore functional C7 in RDEB caused by nonsense mutations. Therefore, aminoglycosides may have therapeutic potential for RDEB patients and other inherited skin diseases caused by nonsense mutations.Molecular Therapy (2014); doi:10.1038/mt.2014.140.
    Original languageEnglish
    Pages (from-to)1741-1752
    Number of pages12
    JournalMolecular Therapy
    Volume22
    Issue number10
    DOIs
    Publication statusPublished - 23 Jul 2014

    Fingerprint

    Collagen Type VII
    Epidermolysis Bullosa Dystrophica
    Nonsense Codon
    Aminoglycosides
    Skin
    Therapeutics
    Paromomycin
    Multiple Trauma
    Gentamicins
    Keratinocytes
    Skin Diseases
    Fibroblasts
    Phenotype
    Cell Line
    Mutation

    Cite this

    Cogan, Jon ; Weinstein, Jacqueline ; Wang, Xinyi ; Hou, Yingping ; Martin, Sabrina ; South, Andrew P. ; Woodley, David T. ; Chen, Mei. / Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons : therapeutic implications for dystrophic epidermolysis bullosa. In: Molecular Therapy. 2014 ; Vol. 22, No. 10. pp. 1741-1752.
    @article{ca05e53efb4d4e55a38892aa25a45e40,
    title = "Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa",
    abstract = "Patients with recessive dystrophic epidermolysis bullosa (RDEB) have severe, incurable skin fragility, blistering, and multiple skin wounds due to mutations in the gene encoding type VII collagen (C7), the major component of anchoring fibrils mediating epidermal-dermal adherence. Nearly 10-25{\%} of RDEB patients carry nonsense mutations leading to premature stop codons (PTCs) that result in truncated C7. In this study, we evaluated the feasibility of using aminoglycosides to suppress PTCs and induce C7 expression in two RDEB keratinocyte cell lines (Q251X/Q251X and R578X/R906) and two primary RDEB fibroblasts (R578X/R578X and R163X/R1683X). Incubation of these cells with aminoglycosides (geneticin, gentamicin, and paromomycin) resulted in the synthesis and secretion of a full-length C7 in a dose-dependent and sustained manner. Importantly, aminoglycoside-induced C7 reversed the abnormal RDEB cell phenotype and incorporated into the dermal-epidermal junction of skin equivalents. We further demonstrated the general utility of aminoglycoside-mediated readthrough in 293 cells transiently transfected with expression vectors encoding 22 different RDEB nonsense mutations. This is the first study demonstrating that aminoglycosides can induce PTC readthrough and restore functional C7 in RDEB caused by nonsense mutations. Therefore, aminoglycosides may have therapeutic potential for RDEB patients and other inherited skin diseases caused by nonsense mutations.Molecular Therapy (2014); doi:10.1038/mt.2014.140.",
    author = "Jon Cogan and Jacqueline Weinstein and Xinyi Wang and Yingping Hou and Sabrina Martin and South, {Andrew P.} and Woodley, {David T.} and Mei Chen",
    year = "2014",
    month = "7",
    day = "23",
    doi = "10.1038/mt.2014.140",
    language = "English",
    volume = "22",
    pages = "1741--1752",
    journal = "Molecular Therapy",
    issn = "1525-0016",
    publisher = "Nature Publishing Group",
    number = "10",

    }

    Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons : therapeutic implications for dystrophic epidermolysis bullosa. / Cogan, Jon; Weinstein, Jacqueline; Wang, Xinyi; Hou, Yingping; Martin, Sabrina; South, Andrew P.; Woodley, David T.; Chen, Mei (Lead / Corresponding author).

    In: Molecular Therapy, Vol. 22, No. 10, 23.07.2014, p. 1741-1752.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons

    T2 - therapeutic implications for dystrophic epidermolysis bullosa

    AU - Cogan, Jon

    AU - Weinstein, Jacqueline

    AU - Wang, Xinyi

    AU - Hou, Yingping

    AU - Martin, Sabrina

    AU - South, Andrew P.

    AU - Woodley, David T.

    AU - Chen, Mei

    PY - 2014/7/23

    Y1 - 2014/7/23

    N2 - Patients with recessive dystrophic epidermolysis bullosa (RDEB) have severe, incurable skin fragility, blistering, and multiple skin wounds due to mutations in the gene encoding type VII collagen (C7), the major component of anchoring fibrils mediating epidermal-dermal adherence. Nearly 10-25% of RDEB patients carry nonsense mutations leading to premature stop codons (PTCs) that result in truncated C7. In this study, we evaluated the feasibility of using aminoglycosides to suppress PTCs and induce C7 expression in two RDEB keratinocyte cell lines (Q251X/Q251X and R578X/R906) and two primary RDEB fibroblasts (R578X/R578X and R163X/R1683X). Incubation of these cells with aminoglycosides (geneticin, gentamicin, and paromomycin) resulted in the synthesis and secretion of a full-length C7 in a dose-dependent and sustained manner. Importantly, aminoglycoside-induced C7 reversed the abnormal RDEB cell phenotype and incorporated into the dermal-epidermal junction of skin equivalents. We further demonstrated the general utility of aminoglycoside-mediated readthrough in 293 cells transiently transfected with expression vectors encoding 22 different RDEB nonsense mutations. This is the first study demonstrating that aminoglycosides can induce PTC readthrough and restore functional C7 in RDEB caused by nonsense mutations. Therefore, aminoglycosides may have therapeutic potential for RDEB patients and other inherited skin diseases caused by nonsense mutations.Molecular Therapy (2014); doi:10.1038/mt.2014.140.

    AB - Patients with recessive dystrophic epidermolysis bullosa (RDEB) have severe, incurable skin fragility, blistering, and multiple skin wounds due to mutations in the gene encoding type VII collagen (C7), the major component of anchoring fibrils mediating epidermal-dermal adherence. Nearly 10-25% of RDEB patients carry nonsense mutations leading to premature stop codons (PTCs) that result in truncated C7. In this study, we evaluated the feasibility of using aminoglycosides to suppress PTCs and induce C7 expression in two RDEB keratinocyte cell lines (Q251X/Q251X and R578X/R906) and two primary RDEB fibroblasts (R578X/R578X and R163X/R1683X). Incubation of these cells with aminoglycosides (geneticin, gentamicin, and paromomycin) resulted in the synthesis and secretion of a full-length C7 in a dose-dependent and sustained manner. Importantly, aminoglycoside-induced C7 reversed the abnormal RDEB cell phenotype and incorporated into the dermal-epidermal junction of skin equivalents. We further demonstrated the general utility of aminoglycoside-mediated readthrough in 293 cells transiently transfected with expression vectors encoding 22 different RDEB nonsense mutations. This is the first study demonstrating that aminoglycosides can induce PTC readthrough and restore functional C7 in RDEB caused by nonsense mutations. Therefore, aminoglycosides may have therapeutic potential for RDEB patients and other inherited skin diseases caused by nonsense mutations.Molecular Therapy (2014); doi:10.1038/mt.2014.140.

    U2 - 10.1038/mt.2014.140

    DO - 10.1038/mt.2014.140

    M3 - Article

    VL - 22

    SP - 1741

    EP - 1752

    JO - Molecular Therapy

    JF - Molecular Therapy

    SN - 1525-0016

    IS - 10

    ER -